Autopsy report · NCT00422565

Zotarolimus-Versus Sirolimus-Versus PacliTaxel-Eluting Stent for Acute Myocardial Infarction Patients

“The recruitment rate was much slower than expected.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months after it had already started.
• Ran for about 1 year 11 months before it stopped.
• 328 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 4

Sponsor

Seung-Jung Park

Sponsor type

University, hospital or other

Conditions

Myocardial Infarction

Interventions

Endeavor, Medtronic; Cypher, Cordis; Taxus Liberte, Boston Scientific

Participants

328

Sites

12

Countries

South Korea

Trials that died the same way

• Pilot Study of Treatment for Subclinical AMR (Antibody-mediated Rejection) in Kidney Transplant Recipients
  “Slower than expected recruitment rate” (89% match in meaning)
• Pharmacokinetics of Ceftolozane/Tazobactam in Patients With Burns
  “Much slower recruitment than anticipated” (87% match in meaning)
• The Effect of Episiotomy on Maternal and Fetal Outcomes (EPITRIAL)
  “Slower than expected recruitment rate, and larger than expected required sample.” (86% match in meaning)
• Serum-derived Bovine Immunoglobulin Effect on Mucositis
  “Recruitment slower than anticipated” (86% match in meaning)
• IU Health Krannert Personalized Medicine Study
  “Slower than anticipated recruitment” (85% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.